165 related articles for article (PubMed ID: 8797480)
21. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
Katayama S
Eur Neurol; 2001; 46 Suppl 1():11-7. PubMed ID: 11741098
[TBL] [Abstract][Full Text] [Related]
22. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Goetz CG; Tanner CM; Glantz RH; Klawans HL
Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Jellinger K
J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
[TBL] [Abstract][Full Text] [Related]
24. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Guttman M
Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Parkinson's disease with dopamine agonists: a review.
Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
[TBL] [Abstract][Full Text] [Related]
26. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease.
Högl B; Rothdach A; Wetter TC; Trenkwalder C
Neuropsychopharmacology; 2003 Oct; 28(10):1866-70. PubMed ID: 12865895
[TBL] [Abstract][Full Text] [Related]
27. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Boguszewski CL; dos Santos CM; Sakamoto KS; Marini LC; de Souza AM; Azevedo M
Pituitary; 2012 Mar; 15(1):44-9. PubMed ID: 21847572
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine versus levodopa in early Parkinson's disease.
Ramaker C; van Hilten JJ
Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
[TBL] [Abstract][Full Text] [Related]
29. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
31. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
Steiger MJ; El-Debas T; Anderson T; Findley LJ; Marsden CD
J Neurol; 1996 Jan; 243(1):68-72. PubMed ID: 8869390
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Schneider E; Hubener K; Fischer PA
Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
[TBL] [Abstract][Full Text] [Related]
33. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.
Korczyn AD; Brunt ER; Larsen JP; Nagy Z; Poewe WH; Ruggieri S
Neurology; 1999 Jul; 53(2):364-70. PubMed ID: 10430427
[TBL] [Abstract][Full Text] [Related]
34. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Hutton JT; Koller WC; Ahlskog JE; Pahwa R; Hurtig HI; Stern MB; Hiner BC; Lieberman A; Pfeiffer RF; Rodnitzky RL; Waters CH; Muenter MD; Adler CH; Morris JL
Neurology; 1996 Apr; 46(4):1062-5. PubMed ID: 8780092
[TBL] [Abstract][Full Text] [Related]
35. Cabergoline : a review of its use in the treatment of Parkinson's disease.
Curran MP; Perry CM
Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Utsumi H;
Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
Baas HK; Schueler P
Eur Neurol; 2001; 46 Suppl 1():18-23. PubMed ID: 11741099
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease: a comparison of mesulergine and bromocriptine.
Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
[TBL] [Abstract][Full Text] [Related]
39. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Inzelberg R; Schechtman E; Nisipeanu P
Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
[TBL] [Abstract][Full Text] [Related]
40. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations.
Tsang KL; Ho SL; Lo SK
Neurology; 2000 Jun; 54(12):2292-8. PubMed ID: 10881255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
